Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
141M
-
Shares change
-
+4.26M
-
Total reported value, excl. options
-
$183M
-
Value change
-
+$5.56M
-
Put/Call ratio
-
0.43
-
Number of buys
-
56
-
Number of sells
-
-51
-
Price
-
$1.30
Significant Holders of Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) as of Q3 2024
159 filings reported holding NKTR - Nektar Therapeutics - Common Stock, par value $0.0001 per share as of Q3 2024.
Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 141M shares
.
Largest 10 shareholders include BlackRock, Inc. (16M shares), Deep Track Capital, LP (15.9M shares), VANGUARD GROUP INC (13.1M shares), EVENTIDE ASSET MANAGEMENT, LLC (9.4M shares), SAMLYN CAPITAL, LLC (9.2M shares), CITADEL ADVISORS LLC (6.95M shares), PRIMECAP MANAGEMENT CO/CA/ (5.91M shares), ACADIAN ASSET MANAGEMENT LLC (5.65M shares), MILLENNIUM MANAGEMENT LLC (5.06M shares), and Nantahala Capital Management, LLC (4.11M shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.